Cemiplimab is approved for the treatment of certain patients with advanced cutaneous squamous cell carcinoma, for patients with locally advanced or metastatic basal cell carcinoma, for the first-line treatment of patients with advanced non–small cell lung cancer with high PD-L1 expression and no EGFR, ALK, or ROS1 aberrations, and in combination with platinum-based chemotherapy for the first-line treatment of patients with advanced non–small cell lung cancer with no EGFR, ALK, or ROS1 aberrations (9). The gene discussed is EGFR; the disease is cutaneous squamous cell carcinoma.